2019
External validation of a prognostic model for overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC).
Halabi S, Dutta S, Araujo J, Logothetis C, Sternberg C, Armstrong A, Carducci M, Chi K, De Bono J, Petrylak D, Fizazi K, Higano C, Small E, Kelly W. External validation of a prognostic model for overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC). Journal Of Clinical Oncology 2019, 37: 5022-5022. DOI: 10.1200/jco.2019.37.15_suppl.5022.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerPrognostic risk groupsMedian overall survivalOverall survivalRisk groupsPrognostic modelCastration-resistant prostate cancerECOG performance statusOpioid analgesic usePhase III trialsHigh groupTime-dependent areaAnalgesic useIII trialsPerformance statusProstate cancerRisk scoreTreatment groupsDisease sitesSpecific subgroupsMonthsCharacteristic curveSimilar resultsMenExternal validation
2009
Correlation of progression-free survival (PFS) and overall survival (OS) in men with metastatic castration-resistant prostate cancer (CRPC) who failed first-line chemotherapy: Results from the SPARC Trial
Halabi S, Sartor O, Petrylak D, Sternberg C, Witjes J, Noursalehi M, McKearn T, George M. Correlation of progression-free survival (PFS) and overall survival (OS) in men with metastatic castration-resistant prostate cancer (CRPC) who failed first-line chemotherapy: Results from the SPARC Trial. Journal Of Clinical Oncology 2009, 27: 5150-5150. DOI: 10.1200/jco.2009.27.15_suppl.5150.Peer-Reviewed Original ResearchProgression-free survivalCastration-resistant prostate cancerFirst-line chemotherapyOverall survivalMetastatic castration-resistant prostate cancerChemotherapy-naïve patientsDouble-blind trialDate of randomizationMedian survival timePredictors of OSProportional hazards modelType of progressionSPARC trialLine chemotherapyCRPC patientsNaïve patientsFirst progressionTau measuresProstate cancerLandmark analysisSurvival timeTreatment groupsHazards modelStratification factorsClinical relevance